Verrica Pharmaceuticals Inc. Cash and Restricted Cash
Verrica Pharmaceuticals Inc. (VRCA) had Cash and Restricted Cash of $11.46 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.46M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.86M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $30.15M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $11.46M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $20.86M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $30.15M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $21.10M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $15.40M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $29.59M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $46.33M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $22.96M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $31.93M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $48.94M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $69.55M 10-K · filed 2026-03-11 |
| 2023-09-30 | $84.31M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $55.14M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $59.95M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $34.27M 10-K · filed 2025-03-11 |
| 2022-09-30 | $32.47M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $45.43M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $50.41M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $15.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | $20.44M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $24.71M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $44.10M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $10.69M 10-K · filed 2023-03-06 |
| 2020-09-30 | $17.20M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $48.93M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $54.49M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $9.24M 10-K · filed 2022-03-02 |
| 2019-09-30 | $10.60M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $19.85M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $24.43M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $10.27M 10-K · filed 2021-03-17 |
| 2018-09-30 | $38.31M 10-Q · filed 2019-11-06 |
| 2017-12-31 | $8.66M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |